Patent intelligence · US
US 11807649
Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2
Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2
Patent details — US 11807649
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 7, 2023
- Expiration
- Nov 2, 2043
- Applicant
- EnLiven Therapeutics, Inc.
- Claims
- 44
- CPC classes
- A61P, A61P35/02
Quick answer
US 11807649 (Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2) is held by EnLiven Therapeutics, Inc.. Status: granted. Granted Nov 7, 2023. Expires Nov 2, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- EnLiven Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 44
- CPC classes
- A61P, A61P35/02
More from EnLiven Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12240846
5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases
granted -
US 11807638
5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases
granted -
US 11767321
5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases
granted -
US 10888597
Composition for treating brain stroke
granted
Frequently asked questions
What is US patent 11807649?
US 11807649 (Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2) is held by EnLiven Therapeutics, Inc.. Status: granted. Granted Nov 7, 2023. Expires Nov 2, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11807649?
EnLiven Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.
When does US 11807649 expire?
Our index shows an expiration date of Nov 2, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.